Online inquiry

IVTScrip™ mRNA-Anti-RSPO3, OMP-131R10(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ12648MR)

This product GTTS-WQ12648MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets RSPO3 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_032784.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 84870
UniProt ID Q9BXY4
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-RSPO3, OMP-131R10(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ12648MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ4819MR IVTScrip™ mRNA-Anti-CD4, BT-061(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BT-061
GTTS-WQ1595MR IVTScrip™ mRNA-Anti-GDF11, ACE-536(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ACE-536
GTTS-WQ7407MR IVTScrip™ mRNA-Anti-EGFR, GA201(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA GA201
GTTS-WQ15933MR IVTScrip™ mRNA-Anti-Felcat NGF, ZTS-00084768(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ZTS-00084768
GTTS-WQ11843MR IVTScrip™ mRNA-Anti-TIGIT, MK-7684(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MK-7684
GTTS-WQ5971MR IVTScrip™ mRNA-Anti-IL6, CLLB8(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CLLB8
GTTS-WQ12806MR IVTScrip™ mRNA-Anti-MASP2, OMS721(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA OMS721
GTTS-WQ13669MR IVTScrip™ mRNA-Anti-TNFSF13B, RC18(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA RC18
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW